Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 74, Issue 1, 2015, Pages 119-123

  Van Sijl, Alper M ^a,b,c   Van Eijk, Izhar C ^a   Peters, Mike J L ^c   Serné, Erik H ^c   Van Der Horst Bruinsma, Irene E ^a   Smulders, Yvo M ^c   Nurmohamed, Michael T ^a,b,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Rheumatology Jan van Breemen Research Institute Reade ^*  (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELASTICITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RISK ASSESSMENT; YOUNG MODULUS; ANTAGONISTS AND INHIBITORS; ARTERIAL STIFFNESS; ASYMPTOMATIC DISEASE; CAROTID ARTERY; CAROTID ARTERY DISEASE; COMPLICATION; ECHOGRAPHY; MIDDLE AGED; RISK FACTOR; SPONDYLITIS, ANKYLOSING;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ASYMPTOMATIC DISEASES; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; COHORT STUDIES; DISEASE PROGRESSION; ELASTIC MODULUS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR STIFFNESS;

EID: 84918534573     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203934     Document Type: Article

References (31)

1. Peters MJ, Van der Horst-Bruinsma I, Dijkmans BA, et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34:585-92.
2. Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011;63:3294-304.
3. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52:174-6.
4. O'Neill TW, Bresnihan B. The heart in ankylosing spondylitis. Ann Rheum Dis 1992;51:705-6.
5. O'Neill TW, King G, Graham IM, et al. Echocardiographic abnormalities in ankylosing spondylitis. Ann Rheum Dis 1992;51:652-4.
6. Mathieu S, Gossec L, Dougados M, et al. Cardiovascular profile in ankylosing spondylitis. A systematic review and metaanalysis. Arthritis Care Res (Hoboken) 2010;63:557-63.
7. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011;70:1921-5.
8. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002;90:18L-21L.
9. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459-67.
10. Gonzalez-Juanatey C, Llorca J, Martin J, et al. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009;38:366-71.
11. Bots ML, Dijk JM, Oren A, et al. Carotid intima-media thickness, arterial stiffness and risk of cardiovascular disease: current evidence. J Hypertens 2002;20:2317-25.
12. Mattace-Raso FU, Van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006;113:657-63.
13. Peters MJL, Van Eijk IC, Smulders YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010;37:161-6.
14. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009;88:358-65.
15. Mathieu S, Joly H, Baron G, et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 2008;47:1203-7.
16. Cece H, Yazgan P, Karakas E, et al. Carotid intima-media thickness and paraoxonase activity in patients with ankylosing spondylitis. Clin Invest Med 2011;34:E225.
17. Hamdi W, Bouaziz MC, Zouch I, et al. Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2012;39:322-6.
18. Capkin E, Karkucak M, Kiris A, et al. Anti-TNF-alpha therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology (Oxford) 2012;51:910-14.
19. Angel K, Provan SA, Fagerhol MK, et al. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012;25:644-50.
20. Mathieu S, Pereira B, Couderc M, et al. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology (Oxford) 2013;52:204-9.
21. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
22. Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken) 2011;63(Suppl. 11):S47-58.
23. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl. 2):ii1-44.
24. Giles JT, Post WS, Blumenthal RS, et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2011;63:3216-25.
25. Bodnar N, Kerekes G, Seres I, et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 2011;38:723-9.
26. Capkin E, Kiris A, Karkucak M, et al. Investigation of effects of different treatment modalities on structural and functional vessel wall properties in patients with ankylosing spondylitis. Joint Bone Spine 2010;78:378-82.
27. Peters M, Visman I, Nielen M, et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010;69:579-81.
28. Van Eijk IC, Peters MJL, Serne EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 2009;68:362-6.
29. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011;63:522-9.
30. Miranda-Filloy JA, Llorca J, Carnero-Lopez B, et al. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol 2012;30:850-5.
31. Del Rincon I, Williams K, Stern MP, et al. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48:1833-40.